Kanjinti (trastuzumab-anns) is used to treat stomach and
breast cancer. Kanjinti is a biosimilar for
herceptin (trastuzumab). Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. Kanjinti may be covered by your Medicare or insurance plan. With the Patient Assistance Program from Genentech, you can receive your medication at no cost.